Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

tradersunion353 Jul. 27 at 11:08 AM

$ABCL another 10% drop just for fun,? why not?? pos company

0 · Reply

Stocktradesmoon Jul. 27 at 3:07 AM

$ABCL I don't give a FUCK if you have $1000, $10,000 or even $100,000 in your portfolio, Biotech stocks are going to make people generational WEALTH this year.

0 · Reply

snowPOW Jul. 27 at 2:14 AM

$ABCL hey @DeMampCamp That poster was beyond the pale. @Stocktwits Not ok on this board or any other. Blocked and reported. Good to have positive conversation about ABCL and know that as a fellow poster of this board, I won't tolerate that BS. Cheers

1 · Reply

snowPOW Jul. 27 at 2:09 AM

$ABCL https://www.wsj.com/health/pharma/regeneron-george-yancopoulos-drug-discovery-17fea3fa Probably noteworthy, please let me know if it's not.

0 · Reply

Austinhilton Jul. 26 at 3:05 PM

Buying fundamentally undervalued positions while having your average around their 200 WMA will always protect you Your strategy is time then Anyone that has an issue holding should not be investing. $MRK $CABA $ABCL $LEU

0 · Reply

tradersunion353 Jul. 26 at 1:10 PM

$ABCL there is some paid group or big bag holders on x and here . whenever stock drops - they flood the platforms with posts that yhry are adding this is a gift . clowns have been misleading investors for last 5 years .. stay away from this pumpers

1 · Reply

tradersunion353 Jul. 26 at 12:56 PM

$ABCL abcl 635 phase 2 leaked data was bad and stock crashed almost 50% in 2 weeks pos management didnt even do a pr for investors.. what kind of trash biotech is this

0 · Reply

tradersunion353 Jul. 26 at 12:51 PM

$ABCL still dont get it junk drops from 8.40s to 5 dollars in 2 weeks what are this clowns celebrating for?? no real long term investor would celebrate clowns 🤡🤡🤡🤡

0 · Reply

Stocktradesmoon Jul. 25 at 6:45 PM

$ABCL $ABCL is two businesses stapled together: a partner platform earning milestones on molecules it never funded, and an owned pipeline led by ABCL635 that could re rate the whole thing. The market prices the first and ignores the second.

0 · Reply

Stocktradesmoon Jul. 25 at 6:44 PM

$ABCL $ABCL + Jazz T-cell collab. ABCL635 data already positive. Most still see a tool company. August 5 coming.

0 · Reply

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

Jul 7, 2026, 4:05 PM EDT - 19 days ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-07T10:35:14.000Z - 20 days ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

2026-07-06T13:15:29.000Z - 21 days ago

AbCellera apponts Lynn Seely to board of directors

LYEL

Jul 6, 2026, 9:00 AM EDT - 21 days ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jun 17, 2026, 7:43 AM EDT - 5 weeks ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jun 17, 2026, 7:00 AM EDT - 5 weeks ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

2026-06-05T13:05:56.000Z - 7 weeks ago

AbCellera appoints Victor Sandor to board of directors

Jun 5, 2026, 9:00 AM EDT - 7 weeks ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 4, 2026, 11:40 AM EDT - 7 weeks ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 2 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T10:58:11.000Z - 2 months ago

AbCellera price target raised to $8 from $7 at Stifel

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 2 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

2026-05-05T10:36:31.000Z - 2 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 3 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 3 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

2026-04-09T20:10:26.000Z - 3 months ago

AbCellera initiated with a Buy at JonesResearch

Apr 1, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 4 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 5 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Slides: Q4 2025

2026-02-24T21:15:21.000Z - 5 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

Feb 24, 2026, 4:05 PM EST - 5 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 5 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 6 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 6 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 6 months ago

AbCellera Biologics Slides: Corporate presentation

2026-01-12T14:36:23.000Z - 6 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

Jan 12, 2026, 9:00 AM EST - 6 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

2025-12-18T14:20:19.000Z - 7 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

Dec 18, 2025, 9:00 AM EST - 7 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 8 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 8 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 11 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 11 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 27, 2025, 9:00 AM EDT - 11 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 17, 2024, 11:30 AM EDT - 2 years ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 2 years ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 2 years ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

tradersunion353 Jul. 27 at 11:08 AM

$ABCL another 10% drop just for fun,? why not?? pos company

0 · Reply

Stocktradesmoon Jul. 27 at 3:07 AM

$ABCL I don't give a FUCK if you have $1000, $10,000 or even $100,000 in your portfolio, Biotech stocks are going to make people generational WEALTH this year.

0 · Reply

snowPOW Jul. 27 at 2:14 AM

1 · Reply

snowPOW Jul. 27 at 2:09 AM

$ABCL https://www.wsj.com/health/pharma/regeneron-george-yancopoulos-drug-discovery-17fea3fa Probably noteworthy, please let me know if it's not.

0 · Reply

Austinhilton Jul. 26 at 3:05 PM

0 · Reply

tradersunion353 Jul. 26 at 1:10 PM

1 · Reply

tradersunion353 Jul. 26 at 12:56 PM

$ABCL abcl 635 phase 2 leaked data was bad and stock crashed almost 50% in 2 weeks pos management didnt even do a pr for investors.. what kind of trash biotech is this

0 · Reply

tradersunion353 Jul. 26 at 12:51 PM

$ABCL still dont get it junk drops from 8.40s to 5 dollars in 2 weeks what are this clowns celebrating for?? no real long term investor would celebrate clowns 🤡🤡🤡🤡

0 · Reply

Stocktradesmoon Jul. 25 at 6:45 PM

0 · Reply

Stocktradesmoon Jul. 25 at 6:44 PM

$ABCL $ABCL + Jazz T-cell collab. ABCL635 data already positive. Most still see a tool company. August 5 coming.

0 · Reply

Stockholde Jul. 25 at 4:59 PM

$ABCL i have accumulated about 1k shares without much sweat till now should i keep buying? Average cost 6 bucks

0 · Reply

JennyRowes Jul. 25 at 2:52 PM

$ABCL what comes next??

0 · Reply

PolarBear1 Jul. 25 at 2:05 PM

$ABCL I’d love to know who bought/sold that 2 million share block AH yesterday!?

1 · Reply

tradersunion353 Jul. 25 at 1:11 PM

$ABCL next week we will low 4s Paper trader clowns can keep aadding , loading commenting this prcr is a gift for eterninity shame on management for not commenting on bada phase 2 data that was leaked recently

0 · Reply

PLTRLONGDONG Jul. 25 at 3:03 AM

$ABCL wheres your proof of the leak… still havent seen it? sit and spin while we run it to $200 in 5 years

1 · Reply

MaryHiggins354 Jul. 24 at 8:24 PM

$ABCL CEO Carl Hansen highlighted the long-term vision around building deep-tech companies that can drive innovation in areas like healthcare, energy, and advanced technology. For AbCellera, the focus remains on turning its discovery platform into meaningful partnerships and future therapies. The opportunity is significant, but execution and real-world results will determine the long-term value.

0 · Reply

tradersunion353 Jul. 24 at 7:50 PM

$ABCL every single pumper here deserve this crash clowns have gone mad with restless pumping

0 · Reply

MarketFractal Jul. 24 at 7:47 PM

$ABCL’s long-term thesis is gaining more validation as pharma partnerships continue to develop. Jazz’s upfront payment and milestone commitments for AbCellera’s T cell engager platform highlight growing interest in its technology for solid tumor programs. The key question now is whether these partnerships can translate into successful clinical outcomes and meaningful revenue over time.

0 · Reply

Stocktradesmoon Jul. 24 at 7:19 PM

$ABCL The real $ABCL compounding is the data flywheel. Every campaign they run feeds proprietary data back into the platform, which makes the next campaign better. Software economics quietly showing up in biotech. The moat widens with use, not with spend.

0 · Reply

Stocktradesmoon Jul. 24 at 7:14 PM

$ABCL “If we choose wisely, 20 years from now, we could have global companies—curing cancer, building new energy sources, high-tech, deep-tech businesses that move the country forward.” - Carl Hansen This is our CEO. Deeply invested and aligned with the country’s future 🍀

0 · Reply

Stocktradesmoon Jul. 24 at 7:13 PM

$ABCL AI + pathogens = existential risk. Rapid antibody platforms are the counter. Abcellera already built one (DARPA P3 → COVID proof). That’s the real edge. $ABCL

0 · Reply

Ckkung71 Jul. 24 at 7:02 PM

$ABCL It’s all about the volume. Soon vacation is over .

1 · Reply

Market Cap	1.62B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	6,271,100
Avg Vol	7,238,266
Day's Range	N/A - N/A
Shares Out	305.38M
Stochastic %K	1%
Beta	1.14
Analysts	Strong Sell
Price Target	$10.50